IL246261B - History of benzodiazepines, preparations and methods for the treatment of cognitive impairments - Google Patents
History of benzodiazepines, preparations and methods for the treatment of cognitive impairmentsInfo
- Publication number
- IL246261B IL246261B IL246261A IL24626116A IL246261B IL 246261 B IL246261 B IL 246261B IL 246261 A IL246261 A IL 246261A IL 24626116 A IL24626116 A IL 24626116A IL 246261 B IL246261 B IL 246261B
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- methods
- cognitive impairment
- treating cognitive
- benzodiazepine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361919394P | 2013-12-20 | 2013-12-20 | |
| US201361919390P | 2013-12-20 | 2013-12-20 | |
| US201462075743P | 2014-11-05 | 2014-11-05 | |
| PCT/US2014/071644 WO2015095783A1 (en) | 2013-12-20 | 2014-12-19 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL246261A0 IL246261A0 (en) | 2016-08-02 |
| IL246261B true IL246261B (en) | 2021-03-25 |
Family
ID=53403769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL246261A IL246261B (en) | 2013-12-20 | 2016-06-16 | History of benzodiazepines, preparations and methods for the treatment of cognitive impairments |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10329301B2 (enExample) |
| EP (2) | EP4032889A1 (enExample) |
| JP (3) | JP6883988B2 (enExample) |
| CN (2) | CN106068256B (enExample) |
| AU (1) | AU2014368961B2 (enExample) |
| CA (2) | CA3123897C (enExample) |
| IL (1) | IL246261B (enExample) |
| MX (2) | MX381561B (enExample) |
| NZ (2) | NZ722077A (enExample) |
| WO (1) | WO2015095783A1 (enExample) |
| ZA (1) | ZA201605027B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5916746B2 (ja) | 2010-11-15 | 2016-05-11 | エージンバイオ， インコーポレイテッド | 認知障害を処置するためのピリダジン誘導体、組成物、および方法 |
| AU2014368961B2 (en) | 2013-12-20 | 2019-10-17 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| EP3310785B1 (en) * | 2015-06-19 | 2024-11-20 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US10449181B2 (en) | 2016-08-25 | 2019-10-22 | Sarah E. Labance | Treatment of autism and autism spectrum disorders (ASD) |
| US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US20180170941A1 (en) * | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| MX2020013927A (es) | 2018-06-19 | 2021-03-02 | Agenebio Inc | Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo. |
| CA3129749A1 (en) * | 2019-02-13 | 2020-08-20 | Centre For Addiction And Mental Health | Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors |
| US12187737B2 (en) | 2019-06-04 | 2025-01-07 | Hager Biosciences, Llc | Imidazolo derivatives, compositions and methods as orexin antagonists |
| US20230098667A1 (en) * | 2019-12-19 | 2023-03-30 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| TWI901650B (zh) | 2020-03-26 | 2025-10-21 | 匈牙利商羅特格登公司 | 啶及吡啶并〔３，４－ｃ〕嗒衍生物 |
| MX2023000405A (es) * | 2020-07-10 | 2023-05-10 | Agenebio Inc | Combinaciones de agonistas del receptor a del acido gamma aminobutirico (gabaa) alfa 5 e inhibidores de la glicoproteina de vesicula sinaptica 2a (sv2a) y metodos de uso en el tratamiento del deterioro cognitivo. |
| CA3185573A1 (en) * | 2020-07-10 | 2022-01-13 | Deepa GANDLA | Polymorphs of a gabaa .alpha.5 agonist and methods of using in the treatment of cognitive impairment |
| CN113284553B (zh) * | 2021-05-28 | 2023-01-10 | 南昌大学 | 一种用于治疗药物成瘾的药物靶点结合能力测试方法 |
| HU231691B1 (hu) | 2021-09-29 | 2025-10-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| WO2024039886A1 (en) | 2022-08-19 | 2024-02-22 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
| US20250375429A1 (en) | 2024-05-29 | 2025-12-11 | Smarter Not Harder, Inc. | Obligate pairing of orthosteric and non-orthosteric gaba ligands in pharmaceutical formulations |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| ES413944A1 (es) | 1972-04-20 | 1976-06-01 | Merz & Co | Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5. |
| NL7605526A (nl) | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
| JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US4816456A (en) | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
| HU201906B (en) | 1987-03-04 | 1991-01-28 | Sandoz Ag | Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| CA2000786C (en) | 1988-11-07 | 1999-01-26 | Janssen Pharmaceutica, Naamloze Vennootschap | 3-piperidinyl-1,2-benzisoxazoles |
| US5043345A (en) | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
| DE58905637D1 (de) | 1989-04-14 | 1993-10-21 | Merz & Co Gmbh & Co | Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie. |
| DK0402644T3 (da) | 1989-05-19 | 1996-01-02 | Hoechst Roussel Pharma | N-(Aryloxyalkyl)-heteroarylpiperidiner og -heteroarylpiperaziner, fremgangsmåde til deres fremstilli ng samt deres anvendelse som medikamenter |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
| JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| ATE180475T1 (de) | 1990-09-21 | 1999-06-15 | Rohm & Haas | Dihydropyridazinone und pyridazinone als fungizide |
| US5190951A (en) | 1990-10-19 | 1993-03-02 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| WO1992020682A1 (en) | 1991-05-24 | 1992-11-26 | E.I. Du Pont De Nemours And Company | Arthropodicidal anilides |
| US5106856A (en) | 1991-06-07 | 1992-04-21 | Hoechst-Roussel Pharmaceuticals Inc. | [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds |
| TW201311B (enExample) | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
| US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| CN1079670C (zh) | 1994-03-02 | 2002-02-27 | 阿克佐诺贝尔公司 | 舌下或颊给药的药物组合物 |
| US6479523B1 (en) | 1997-08-26 | 2002-11-12 | Emory University | Pharmacologic drug combination in vagal-induced asystole |
| AU1041599A (en) | 1997-11-13 | 1999-06-07 | Jose Luis Castro Pineiro | Therapeutic uses of triazolo-pyridazine derivatives |
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| US6294583B1 (en) | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| AU1816900A (en) | 1998-11-12 | 2000-05-29 | Merck & Co., Inc. | Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same |
| DE60014043T2 (de) | 1999-03-03 | 2005-09-29 | Eisai Co., Ltd. | Flouride von 4-substituierten piperidin-derivaten |
| GB9911802D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911803D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911804D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9929569D0 (en) | 1999-12-14 | 2000-02-09 | Merck Sharp & Dohme | Therapeutic agents |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US20020151591A1 (en) | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
| TWI239333B (en) * | 2000-11-16 | 2005-09-11 | Hoffmann La Roche | Benzodiazepine derivatives as GABA A receptor modulators |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| CA2439581A1 (en) | 2001-03-01 | 2002-09-12 | Pfizer Products Inc. | Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders |
| US6686352B2 (en) * | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| AU2002313737A1 (en) | 2001-08-13 | 2003-04-01 | University Of Kentucky Research Foundation | Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment |
| US20060167032A1 (en) | 2002-01-16 | 2006-07-27 | Galer Bradley S | Pharmaceutical composition and method for treating disorders of the central nervous system |
| EP1532120B1 (en) | 2002-08-13 | 2009-01-14 | MERCK SHARP & DOHME LTD. | Phenylpyridazine derivatives as ligands for gaba receptors |
| GB0218876D0 (en) | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| US7635709B2 (en) | 2002-09-26 | 2009-12-22 | The United States Of America As Represented By The Department Of Veterans Affairs | Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction |
| CN100339070C (zh) | 2002-10-24 | 2007-09-26 | 莫茨药物股份两合公司 | 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物 |
| ATE540129T1 (de) | 2002-11-22 | 2012-01-15 | Univ Johns Hopkins | Target zur therapie kognitiver behinderungen |
| US20050113458A1 (en) | 2003-10-22 | 2005-05-26 | Forest Laboratories, Inc. | Use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic a-beta peptides in amyloidopathies |
| AU2005286672B2 (en) | 2004-09-23 | 2009-03-12 | Merz Pharma Gmbh & Co. Kgaa | Memantine for the treatment of childhood behavioral disorders |
| ATE402707T1 (de) | 2004-10-12 | 2008-08-15 | Hoffmann La Roche | Imidazoä1,5aütriazoloä1,5dübenzodiazepin- derivative zur behandlung kognitiver störungen |
| NZ554439A (en) * | 2004-10-20 | 2009-09-25 | Hoffmann La Roche | Imidazo-benzodiazepine derivatives |
| JP4751398B2 (ja) * | 2004-10-20 | 2011-08-17 | エフ．ホフマン−ラ ロシュ アーゲー | ハロゲン置換ベンゾジアゼピン誘導体 |
| MX2007007115A (es) | 2004-12-14 | 2007-07-11 | Hoffmann La Roche | Imidazo-benzodiazepinas tetraciclicas como moduladoras del receptor del acido gamma-aminobutirico (gaba). |
| US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| EP1888594A2 (en) | 2005-05-16 | 2008-02-20 | Wisys Technology Foundation, Inc. | Gabaergic agents to treat memory deficits |
| EP2682481A3 (en) | 2005-08-03 | 2014-09-17 | The Johns-Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| US8510055B2 (en) | 2005-08-03 | 2013-08-13 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| AU2006301377B2 (en) * | 2005-10-11 | 2012-03-08 | F. Hoffmann-La Roche Ag | Imidazo benzodiazepine derivatives |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| WO2010014220A1 (en) | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
| US20110136762A1 (en) | 2008-09-24 | 2011-06-09 | E.I. Du Pont De Nemours And Company | Fungicidal pyridazines |
| JP2012503642A (ja) | 2008-09-25 | 2012-02-09 | バイブ ナノ， インコーポレイテッド | ポリマーナノ粒子を製造する方法および活性成分の処方 |
| WO2010120370A2 (en) | 2009-04-17 | 2010-10-21 | Xenoport, Inc. | Gamma-amino-butyric acid derivatives as gabab receptor ligands |
| JP2013516497A (ja) | 2010-01-11 | 2013-05-13 | ミスリィディオン，インク． | 認知増強のための化合物と組成物、製造方法、および治療方法 |
| PH12013500676A1 (en) * | 2010-11-05 | 2013-05-06 | Hoffmann La Roche | Use of active pharmaceutical compounds for the treatment of central nervous system conditions |
| JP2013542266A (ja) * | 2010-11-15 | 2013-11-21 | エージンバイオ， インコーポレイテッド | 認知障害を処置するためのベンゾジアゼピン誘導体、組成物、および方法 |
| JP5916746B2 (ja) | 2010-11-15 | 2016-05-11 | エージンバイオ， インコーポレイテッド | 認知障害を処置するためのピリダジン誘導体、組成物、および方法 |
| JPWO2012161133A1 (ja) | 2011-05-20 | 2014-07-31 | 日産化学工業株式会社 | 置換ピリダジン化合物及び農園芸用殺菌剤 |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| AU2013312240A1 (en) | 2012-09-10 | 2015-03-19 | Ophirex Inc. | Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade |
| AU2014368961B2 (en) | 2013-12-20 | 2019-10-17 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| EP3310785B1 (en) | 2015-06-19 | 2024-11-20 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN108567787A (zh) | 2017-03-10 | 2018-09-25 | 辛衍雪 | 一种治疗慢性阻塞性肺病的药物组合物 |
| MX2020013927A (es) | 2018-06-19 | 2021-03-02 | Agenebio Inc | Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo. |
-
2014
- 2014-12-19 AU AU2014368961A patent/AU2014368961B2/en active Active
- 2014-12-19 EP EP21213904.2A patent/EP4032889A1/en active Pending
- 2014-12-19 NZ NZ722077A patent/NZ722077A/en unknown
- 2014-12-19 CA CA3123897A patent/CA3123897C/en active Active
- 2014-12-19 EP EP14870710.2A patent/EP3083569B1/en active Active
- 2014-12-19 JP JP2016541280A patent/JP6883988B2/ja active Active
- 2014-12-19 US US15/104,494 patent/US10329301B2/en active Active
- 2014-12-19 NZ NZ760341A patent/NZ760341A/en unknown
- 2014-12-19 CN CN201480073611.7A patent/CN106068256B/zh active Active
- 2014-12-19 MX MX2016007808A patent/MX381561B/es unknown
- 2014-12-19 WO PCT/US2014/071644 patent/WO2015095783A1/en not_active Ceased
- 2014-12-19 CN CN202010983158.0A patent/CN112409363B/zh active Active
- 2014-12-19 MX MX2019010577A patent/MX391314B/es unknown
- 2014-12-19 CA CA2934553A patent/CA2934553C/en active Active
-
2016
- 2016-06-16 IL IL246261A patent/IL246261B/en active IP Right Grant
- 2016-07-19 ZA ZA2016/05027A patent/ZA201605027B/en unknown
-
2019
- 2019-05-31 US US16/428,394 patent/US11142529B2/en active Active
- 2019-10-24 JP JP2019193538A patent/JP2020011998A/ja active Pending
-
2021
- 2021-03-01 JP JP2021031721A patent/JP2021080287A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201605027B (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| IL278018A (en) | Methods for the treatment or prevention of ophthalmological conditions | |
| PL2986304T3 (pl) | Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania | |
| IL267451A (en) | Benzodiazepine derivatives, compounds, and methods for treating cognitive impairment | |
| IL246023B (en) | Methods and preparations for the treatment of age-related conditions | |
| EP2986140A4 (en) | COMPOSITIONS, PROCESSES AND KIT FOR TREATMENT OF PETS | |
| PL3012012T3 (pl) | Urządzenie filtracyjne, zastosowanie takiego urządzenia filtracyjnego, oraz sposób pracy takiego urządzenia filtracyjnego | |
| GB201314917D0 (en) | Treated Tobacco and processes for preparing the same, Devices including the same and uses thereof | |
| EP2900175A4 (en) | METHODS, SYSTEMS, AND DEVICES FOR PROCESSING HYPERTENSION | |
| ZA201800360B (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| EP3077049A4 (en) | Compositions and methods for treating vitiligo | |
| IL239921A0 (en) | Preparations containing solutions in solid state and their use for the treatment of pain | |
| EP2941421A4 (en) | COUMESTAN, COUMESTROL, COUMESTAN DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF | |
| EP2897689A4 (en) | COMPOSITIONS AND METHODS OF TREATING ALOPEZIA | |
| EP3074026A4 (en) | Composition, system and method for treating skin | |
| ZA201506330B (en) | Methods and compositions for treating leukemia | |
| EP3052102A4 (en) | Compositions and methods for treating cancers | |
| EP3065829A4 (en) | Compositions and methods for treating melanoma | |
| SG10201710538XA (en) | Compositions and methods for treating skin | |
| ZA201600015B (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| EP3089745A4 (en) | Compounds, compositions, and methods for the treatment of cancers | |
| SG10201408836PA (en) | Method and system for sharing radio spectrum | |
| BR112015013145A2 (pt) | canal de alimentação, e, método de formar o mesmo | |
| EP3082859A4 (en) | Compositions and methods for treating sarcoma | |
| EP2990088A4 (en) | HOLDER FOR FILTER AND FILTER THEREFORE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |